source
- Novo and Pfizer say MFN pricing agreements remain unchanged despite Democratic gains in CongressOn their third‑quarter earnings calls, the CEOs of Novo Nordisk and Pfizer said the Most Favored Nation drug‑pricing contracts they signed under the previous administration are still in effect and…
- Sanofi drops Nurix STAT6 degrader program amid molecule-specific concernsSanofi has halted development of an early‑stage STAT6 degrader program that it licensed from Nurix Therapeutics. The decision was announced after the asset entered Phase 1 trials for type 2 inflamm…